氯吡格雷抵抗在脑梗死患者中的动态观察

卒中杂志 ›› 2012, Vol. 7 ›› Issue (11): 852-857.

氯吡格雷抵抗在脑梗死患者中的动态观察

石红婷1，周伯荣2，王融3，邓燕华2，关海涛2，刘子凡2

1广州医学院第四附属医院神经内科
2广州医学院第三附属医院神经内科
3广州医学院第三附属医院检验科

收稿日期:2012-02-21 出版日期:2012-11-20 发布日期:2012-11-20
通讯作者: 周伯荣
基金资助:
广东省科技计划项目（粤科计字【2008】146号）

Dynamic Observation of Clopidogrel Resistance in Patients with Cerebral Infarction

*Department of cerebrovascular, The Forth Affiliated Union Hospital of Guangzhou Medical College, Guangzhou 510150, China

Received:2012-02-21 Online:2012-11-20 Published:2012-11-20
Contact: ZHOU Bo-Rong

摘要/Abstract

摘要：

【摘要】目的探讨氯吡格雷抵抗（clopidogrel resistance，CR）在脑梗死患者中的动态变化；观察脑梗死组与高危组（脑梗死高危因素）CR发生率及血小板聚集率变化情况。方法收集健康对照组68例、高危组59例、脑梗死组121例，采用光比浊法分别测定入组（氯吡格雷75 mg/d）2周后的血小板聚集率；服药2周后，出现CR者换用或联合其他抗血小板药物治疗，并检测其2周后的血小板聚集率的变化；非CR的脑梗死患者维持常规治疗，观察3个月、6个月后血小板聚集率的变化。结果服药前，脑梗死组［（65.75±13.11）%］分别与健康对照组［（50.49±12.42）%］、高危组［（56.71±11.33）%］比较血小板聚集率，差异有显著性（t =4.534，P =0.000；t =7.829，P =0.000）；服药2周后，高危组CR发生率为13.6%（8例），脑梗死组的发生率为29.75%（36例），且两组患者发生CR的患者中患糖尿病比例均较高（分别为50%和41.67%）；换用或联合其他抗血小板药物治疗后，70%CR者的血小板聚集率下降>10%；服药3个月后脑梗死组未见新CR；服药6个月后脑梗死组新发CR者15例（17.65%）。结论脑梗死组CR发生率较高，CR在脑梗死患者中可能存在时相动态变化。

关键词: 脑梗死; 血小板; 氯吡格雷抵抗

Abstract:

Objective To investigate the dynamic changes in patients with cerebral infarction(CI) of clopidogrel resistance(CR), and to observe the change of rate of platelet aggregation(△RPA) and the incidence rate of CR in patients with ischemic stroke and high risk(high risk factors of stroke).

Methods Sixty-eight cases in normal people and 59 cases in patients with high risk(HR) and 121 cases in patients with CI were enrolled. The rate of platelet aggregation(RPA) was examined on baseline and two weeks after medication(clopidogrel 75 mg/d). The patients who had CR were used or combined with other antiplatelet drug to investigate the △RPA after two weeks. Patients who had non-CR continued to be given clopidogrel 75 mg/d to investigate △RPA after three months and six months.

Results Before overdosed, CI group([65.75±13.11]%) respectively compared with normal group([50.49±12.42]%) and HR group([56.71±11.33]%), which the RPA had a significant difference(t =4.534, P =0.000 vs t =7.829, P =0.000); The incidence of CR in patients with HR was 13.6%(8 cases), the incidence of CR in patients with CI was 29.75%(36 cases). Three months after overdosed the incidence of new CR in patients with CI was not detected, six months after overdosed the incidence of new CR in patients with CI was 17.65%; When other antiplatelet drug were used, RPA decreased by >10% in 70% CR patients.

Conclusion The incidence of CR in patients with CI was higher. Dynamic changes of CR may occur in patients with CI

Key words: Cerebral infarction; Platelet;; Clopidogrel resistance

石红婷1，周伯荣2，王融3，邓燕华2，关海涛2，刘子凡2. 氯吡格雷抵抗在脑梗死患者中的动态观察[J]. 卒中杂志, 2012, 7(11): 852-857.

SHI Hong-Ting*, ZHOU Bo-Rong, WANG Rong, DENG Yan-Hua, GUAN Hai-Tao, LIU Zi-Fan.. Dynamic Observation of Clopidogrel Resistance in Patients with Cerebral Infarction[J]. Chinese Journal of Stroke, 2012, 7(11): 852-857.

参考文献

参考文献

1 Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction:randomised placebo-controlled trial[J]. Lancet, 2005, 366:1607-1621.

2 Sofi F, Marcucci R, Gori AM, et al. Clopidogrel nonresponsiveness and risk of cardiovascular morbidity.An updated meta-analysis[J]. Thromb Haemost, 2010,103:841-848.

3 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治指南2010[J]. 中华神经科杂志, 2010, 43:146-153.

4 Han SW, Kim SH, Lee JY, et al. A new subtype classification of ischemic stroke based on treatment and etiologic mechanism[J]. Eur Neurol, 2007, 57:96-102.

5 贾建平, 神经病学[M]. 第6版, 北京:人民卫生出版社,2008:153.

6 Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting:response variability, drug resistance,and the effect of pretreatment platelet reactivity[J].Circulation, 2003, 107:2908-2913.

7 Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents.The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology[J]. Eur Heart J,2004, 25:166-181.

8 Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease[J]. J Am Coll Cardiol, 2007, 50:1822-1834.

9 Lee JM, Park S, Shin DJ, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in koreans[J]. Am J Cardiol, 2009,104:46-51.

10 Collet JP, Montalescot G. Platelet function testing and implications for clinical practice[J]. J Cardiovasc Pharmacol Ther, 2009, 14:157-169.

11 Westerbacka J, Yki HJ, Turpeinen A, et al. Inhibition of platelet-collagen interaction:an in vivo action of insulin abolished by insulin resistance in obesity[J].Arterioscler Thromb Vasc Biol, 2002, 22:167-172.

12 Lepantalo A, Virtanen KS, Heikkila AJ, et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions[J]. Eur Heart J, 2004, 25:476-483.

13 Matsano H, Tokuda H, Ishisaki A, et al. P2Y12 receptors play significant role in the development of platelet microaggregation in patients with diabetes[J].J Clin Endocrinol Metab, 2005, 90:920-927.

14 Andreas S, Daniela F, Martin E, et al. Rosuvstatin reduces platelet activation in heart failure role of no bioavailability[J]. Arterioscler Thromb Vasc Biol,2005, 25:1071-1077.

[1]	李如娟, 杨川, 马晓辉, 侯焕峰, 付会杰, 马晓丹, 方军涛, 靳金灵, 杨金波. DSA评估无症状大脑中动脉闭塞患者侧支循环状态研究 [J]. 中国卒中杂志, 2022, 17(12): 1355-1359.
[2]	孟一然, 王卫. 椎动脉残端综合征致后循环反复梗死1例并文献复习[J]. 中国卒中杂志, 2022, 17(12): 1381-1384.
[3]	胡红梅, 杨磊, 于玲, 秦伟, 白明悦, 胡文立. 急性单发小脑小梗死的临床特征 [J]. 中国卒中杂志, 2022, 17(11): 1221-1226.
[4]	刘亚杰, 李玉娣, 黎凯锋, 陈哲锋, 凌莉. 基于高通量RNA-Seq技术探讨补阳还五汤治疗小鼠脑梗死的作用机制 [J]. 中国卒中杂志, 2022, 17(11): 1238-1246.
[5]	王磊, 周春亭, 方洋, 王朝晖. 2例椎动脉漂浮血栓的治疗体会[J]. 中国卒中杂志, 2022, 17(11): 1247-1251.
[6]	林庆金, 杨雅玲, 卢武生. 寰椎变异致反复脑梗死1例报道[J]. 中国卒中杂志, 2022, 17(11): 1252-1256.
[7]	罗秋雁, 黄文利, 冯慧宇, 陈玲, 周鸿雁. 脑室出血合并大面积脑梗死1例报道并文献复习[J]. 中国卒中杂志, 2022, 17(10): 1103-1107.
[8]	杨金波, 张英魁. 到底应该用面积还是用体积描述梗死病灶？[J]. 中国卒中杂志, 2022, 17(10): 1112-1113.
[9]	张亮, 黄立安, 徐安定. CHANCE 2开创了基因指导下卒中抗血小板治疗的先河[J]. 中国卒中杂志, 2022, 17(08): 807-812.
[10]	孔晓彤, 刘佩芳, 蔡涵璐, 王宇, 王丽华. 基于快速CYP2C19基因检测的快代谢型急性轻型缺血性卒中双抗治疗1例报道[J]. 中国卒中杂志, 2022, 17(08): 814-816.
[11]	冯博, 赵彩君, 常立国. 基于快速CYP2C19基因检测发现携带功能缺失等位基因的急性轻型缺血性卒中双抗治疗1例报道[J]. 中国卒中杂志, 2022, 17(08): 817-820.
[12]	何俊芳, 刘新平, 吕学海, 王斌. PI3K/AKT信号通路介导脂联素对脑缺血再灌注大鼠的保护作用 [J]. 中国卒中杂志, 2022, 17(08): 857-862.
[13]	中国卒中学会神经介入分会. 症状性颅内动脉粥样硬化性狭窄血管内治疗中国专家共识2022[J]. 中国卒中杂志, 2022, 17(08): 863-888.
[14]	闫志杰, 曲庆明, 张淇, 张永丽, 樊启为, 吕海东, 贾杰. 缺血性卒中患者基于心肺适能个体化训练1例报告[J]. 中国卒中杂志, 2022, 17(06): 585-588.
[15]	徐冉, 李悦悦, 冯凡凡, 阚伟豪, 董瑞国. 肺癌相关脑梗死的危险因素分析[J]. 中国卒中杂志, 2022, 17(06): 628-633.